Spotlight On
β Often, supportive care is the only option
Latest in Spotlight On
Newest EGFR TKIs have changed the game for treating asymptomatic brain metastases
Key innovations from the ASH annual meeting
Uveitis, psoriasis, IBD are common
One notable study showed improved survival with trastuzumab deruxtecan
Uveitis, psoriasis, IBD are common
One notable study showed improved survival with trastuzumab deruxtecan
More in Spotlight On
But the best strategy for stage I disease is less clear, experts say
Challenges include identifying high-risk patients and optimizing therapy
Transformation occurs in a minority of patients, with an extremely poor prognosis
"It is really a discussion of their individual health conditions," one expert says
Two new drugs offer promise after obeticholic acid misses out on full approval
Disease chronicity and progression raise ongoing questions
More research needed on role of local therapy in new era of treatment
Balancing risk and benefit takes a personal approach with frailty scores, clinical assessments
Expert insights into clinical progress and future perspectives
New research focuses on interventions for highest-risk patients
Though only one approved agent has been available for decades, the armamentarium has expanded
A major reason for the increase in prevalence is increased survival from improved management
While all adults age 75 and up are eligible, here's who's considered high risk in the 60-74 group
"Remarkable" how closely effectiveness in real-world setting matches clinical trial efficacy
